Korbyn Dahlquist, Ph.D. is a research scientist in the Camell lab, where she investigates how the chemotherapeutic agent, doxorubicin, drives immune system dysfunction. Her work also explores immune-metabolic regulation during infectious challenge. Korbyn earned her Ph.D. in June 2025 after completing her dissertation in the Camell lab. She graduated from Bethel University in May 2020 with dual bachelor’s degrees in Biochemistry/Molecular Biology and Chemistry. Outside the lab, she enjoys cooking, spending time on the water, thrifting, playing pickleball, and hanging out with friends and family.